Loading
A phase 2/3 trial of PM8002, FOLFOX, FOLFIRI in colorectal cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT07221357 by Bristol-Myers Squibb, with 990 participants planned, started 2025-12-31 and due to reach its primary completion in 2030-02-02. Interventions recorded: Pumitamig, FOLFOX, FOLFIRI, Bevacizumab, CAPOX. Conditions listed: Untreated, Unresectable, or Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares PM8002, Bristol Myers Squibb, Bevacizumab, Anti-angiogenic therapy.
Shares Bristol Myers Squibb, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Monoclonal antibodies, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares CAPOX (capecitabine, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.